D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=100288
D&D Pharmatech in Talks for Technology Transfer of MASH Therapy Candidate DD01
D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=100079
Samsung Bioepis Holdings to Expand New Drug Development on Biosimilar Success
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
Seo Jin-seok, CEO of Celltrion, Announces Major Expansion of New Drug Development at JPMorgan Healthcare Conference
Celltrion announced at the JPMorgan Healthcare Conference that it will expand its new drug pipeline and U.S. manufacturing, aiming to quadruple its biosimilar portfolio and strengthen its global market position.
SK, Lotte, and Celltrion Heirs Attend JP Morgan Healthcare Conference to Secure Business Momentum
Heirs of SK, Lotte, and Celltrion attended the JP Morgan Healthcare Conference, seeking global partnerships and unveiling strategies to drive growth in the bio sector.
Moderna shares have surged over 20% year-to-date, driven by optimism for its personalized cancer vaccine and anticipation ahead of the JP Morgan Healthcare Conference, though analysts warn of high risks and potential retracement if key catalysts do not materialize.
#YonhapInfomax #Moderna #CancerVaccine #SharePrice #JPmorganHealthcareConference #ClinicalData #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=98935
'Has It Hit Bottom?'—Moderna Shares Surge on Hopes for Cancer Vaccine
Moderna shares have surged over 20% year-to-date, driven by optimism for its personalized cancer vaccine and anticipation ahead of the JP Morgan Healthcare Conference, though analysts warn of high risks and potential retracement if key catalysts do not materialize.
Celltrion to Present New Drug Development Achievements and CMO Vision at JP Morgan Conference
Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
Yonhap Infomax News